Two quarters of softer sales growth for TGTX's Briumvi have likely played a role in the sell off. Briumvi is still growing, with potential for a consolidated dosing regime and a television advertising ...
Briumvi's superior efficacy, safety, and cost advantages are driving strong sales growth and positioning it as a best-in-class RMS therapy. Despite new competition from Roche's SC Ocrevus, Briumvi's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback